Mural Oncology Company Insiders
MURA Stock | 3.44 0.20 5.49% |
Mural Oncology's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Mural Oncology plc suggests that vertually all insiders are panicking. Mural Oncology employs about 107 people. The company is managed by 5 executives with a total tenure of roughly 250 years, averaging almost 50.0 years of service per executive, having 21.4 employees per reported executive.
Mural Oncology's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-10-31 | Adam D Cutler | Disposed 7421 @ 3.41 | View | ||
2024-07-18 | Maiken Keson-Brookes | Disposed 2157 @ 3.41 | View | ||
2024-07-08 | Caroline Loew | Disposed 12531 @ 2.91 | View |
Monitoring Mural Oncology's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Mural |
Mural Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.8105) % which means that it has lost $0.8105 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7834) %, meaning that it created substantial loss on money invested by shareholders. Mural Oncology's management efficiency ratios could be used to measure how well Mural Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of December 17, 2024, Return On Tangible Assets is expected to decline to -0.72. In addition to that, Return On Capital Employed is expected to decline to -0.75. At present, Mural Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 291.2 M, whereas Non Current Assets Total are forecasted to decline to about 22.5 M.The current year's Common Stock Shares Outstanding is expected to grow to about 18.4 M
Mural Oncology Workforce Comparison
Mural Oncology plc is regarded fifth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,159. Mural Oncology holds roughly 107 in number of employees claiming about 9% of equities under Health Care industry.
Mural Oncology Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mural Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mural Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mural Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Goodman Vicki L over a month ago Disposition of 5069 shares by Goodman Vicki L of Mural Oncology at 3.33 subject to Rule 16b-3 | ||
Minegishi Sachiyo over two months ago Insider Trading | ||
Altschuller Susan over three months ago Acquisition by Altschuller Susan of 10000 shares of Mural Oncology at 3.2071 subject to Rule 16b-3 | ||
Golumbeski George over three months ago Insider Trading | ||
Keson-brookes Maiken over three months ago Disposition of 2157 shares by Keson-brookes Maiken of Mural Oncology at 3.41 subject to Rule 16b-3 | ||
Caroline Loew over three months ago Disposition of 12531 shares by Caroline Loew of Mural Oncology at 2.91 subject to Rule 16b-3 | ||
Hickey Benjamin over six months ago Acquisition by Hickey Benjamin of 15021 shares of Mural Oncology at 3.61 subject to Rule 16b-3 | ||
Jackson Scott Thomas over six months ago Insider Trading |
Mural Oncology Notable Stakeholders
A Mural Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mural Oncology often face trade-offs trying to please all of them. Mural Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mural Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Caroline Loew | CEO President | Profile | |
Adam BA | Principal CFO | Profile | |
Justin Levine | Head Resources | Profile | |
Vicki MD | Chief Officer | Profile | |
Maiken KesonBrookes | Chief Officer | Profile |
About Mural Oncology Management Performance
The success or failure of an entity such as Mural Oncology plc often depends on how effective the management is. Mural Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mural management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mural management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.69) | (0.72) | |
Return On Capital Employed | (0.71) | (0.75) | |
Return On Assets | (0.69) | (0.72) | |
Return On Equity | (0.79) | (0.75) |
Please note, the presentation of Mural Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mural Oncology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mural Oncology's management manipulating its earnings.
Mural Oncology Workforce Analysis
Traditionally, organizations such as Mural Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mural Oncology within its industry.Mural Oncology Manpower Efficiency
Return on Mural Oncology Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.9M | |
Net Loss Per Executive | 41.5M | |
Working Capital Per Employee | 2.3M | |
Working Capital Per Executive | 49.7M |
Complementary Tools for Mural Stock analysis
When running Mural Oncology's price analysis, check to measure Mural Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mural Oncology is operating at the current time. Most of Mural Oncology's value examination focuses on studying past and present price action to predict the probability of Mural Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mural Oncology's price. Additionally, you may evaluate how the addition of Mural Oncology to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |